Malignant melanomaSMYTH, J. F.Cancer chemotherapy and biological response modifiers annual. 1991, Vol 12, pp 591-602, issn 0921-4410, 12 p.Article

Malignant melanomaSMYTH, J. F.Cancer chemotherapy and biological response modifiers annual. 1992, Vol 13, pp 588-599, issn 0921-4410Article

Inhibition of cell signalling pathwaysLANGDON, S. P; SMYTH, J. F.Cancer treatment reviews. 1995, Vol 21, Num 1, pp 65-89, issn 0305-7372Article

Method for the determination of γ-L-glutamyl-L-dihydroxyphenylalanine and its major metabolites L-dihydroxypehnylalanine, dopamine and 3,4-dihydroxyphenylacetic acid by high-performance liquid chromatography with electrochemical detectionCUMMINGS, J; MATHESON, L. M; SMYTH, J. F et al.Journal of chromatography. Biomedical applications. 1990, Vol 528, Num 1, pp 43-53, issn 0378-4347Article

Studying lung cancer in the laboratory. II: chemosensitivity testingFERGUSSON, R. J; SMYTH, J. F.Thorax. 1987, Vol 42, Num 11, pp 833-837, issn 0040-6376Article

Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinomaFERGUSSON, R. J; CARMICHAEL, J; SMYTH, J. F et al.Thorax. 1986, Vol 41, Num 5, pp 376-380, issn 0040-6376Article

Cancer genetics and cell and molecular biology : Is this the way Forward ?SMYTH, J. F.Chest. 1996, Vol 109, Num 5, pp 125S-129S, issn 0012-3692, SUPConference Paper

Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography, studies with doxorubicin and NADPH cytochrome P-450 reductaseCUMMINGS, J; BARTOSZEK, A; SMYTH, J. F et al.Analytical biochemistry. 1991, Vol 194, Num 1, pp 146-155, issn 0003-2697, 10 p.Article

Diazepam ablates the constitutional side-effects of gamma interferonBEATTIE, G. J; SMYTH, J. F.Medical oncology and tumor pharmacotherapy. 1988, Vol 5, Num 2, pp 129-130, issn 0736-0118Article

Studying lung cancer in the laboratory. III: Use of cell lines to investigate the biology of lung cancerFERGUSSON, R. J; SMYTH, J. F.Thorax. 1987, Vol 42, Num 12, pp 922-925, issn 0040-6376Article

Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascitesBEATTIE, G. J; SMYTH, J. F.Clinical cancer research. 1998, Vol 4, Num 8, pp 1899-1902, issn 1078-0432Article

Application of high-performance liquid chromatography for recognition of covalent nucleic acid modification with anticancer drugsCUMMINGS, J; FRENCH, R. C; SMYTH, J. F et al.Journal of chromatography. Biomedical applications. 1993, Vol 618, Num 1-2, pp 251-276, issn 0378-4347Article

Interferons in cancer therapy: a reappraisalBALKWILL, F. R; SMYTH, J. F.Lancet (British edition). 1987, Num 8554, pp 317-319, issn 0140-6736Article

Small intestinal mucosal toxicity of cis-platinum ― comparison of toxicity with platinum analogues and dexamethasoneALLAN, S. G; SMYTH, J. F.British journal of cancer. 1986, Vol 53, Num 3, pp 355-360, issn 0007-0920Article

Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumor tissue and antitumour activity : implications for the drugs' in vivo mechanism of actionCUMMINGS, J; ALLAN, L; SMYTH, J. F et al.Biochemical pharmacology. 1994, Vol 47, Num 8, pp 1345-1356, issn 0006-2952Article

Rapid and selective isolation of radiolabelled inositol phosphates from cancer cells using solid-phase extractionANDERSON, L; CUMMINGS, J; SMYTH, J. F et al.Journal of chromatography. Biomedical applications. 1992, Vol 574, Num 1, pp 150-155, issn 0378-4347Article

Studying lung cancer in the laboratory. I: Development of model systemsFERGUSSON, R. J; SMYTH, J. F.Thorax. 1987, Vol 42, Num 10, pp 753-758, issn 0040-6376Article

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancerBROWN, E. R; CHARLES, K. A; DEWITTE, M et al.Annals of oncology. 2008, Vol 19, Num 7, pp 1340-1346, issn 0923-7534, 7 p.Article

The anti-proliferative activity of interferon-γ on ovarian cancer: In vitro and in vivoWALL, L; BURKE, F; SMYTH, J. F et al.Gynecologic oncology (Print). 2003, Vol 88, Num 1, pp S149-S151, issn 0090-8258, 2Conference Paper

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weeklyDAWSON, L. K; JODRELL, D. I; BOWMAN, A et al.European journal of cancer (1990). 2000, Vol 36, Num 18, pp 2353-2359, issn 0959-8049Article

Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic α-picoline derivative, administered intravenouslyJODRELL, D. I; BOWMAN, A; STEWART, M et al.British journal of cancer. 1998, Vol 77, Num 5, pp 808-811, issn 0007-0920Article

Corticosteroids, dopamine antagonists and other drugsHERRSTEDT, J; AAPRO, M. S; SMYTH, J. F et al.Supportive care in cancer. 1998, Vol 6, Num 3, pp 204-214, issn 0941-4355Conference Paper

Transforming growth factor-β isoform expression in human ovarian tumoursBARTLETT, J. M; LANGDON, S. P; SCOTT, W. N et al.European journal of cancer (1990). 1997, Vol 33, Num 14, pp 2397-2403, issn 0959-8049Article

Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas : Phase II study of the EORTC early clinical trials groupMONFARDINI, S; SORIO, R; CAVALLI, F et al.Oncology. 1996, Vol 53, Num 2, pp 163-168, issn 0030-2414Article

Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivoCHIRREY, L; CUMMINGS, J; HALBERT, G. W et al.Cancer chemotherapy and pharmacology. 1995, Vol 35, Num 4, pp 318-322, issn 0344-5704Article